Shopping Cart 0
Cart Subtotal
USD 0

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018

 

Summary

 

GlobalData's clinical trial report, Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018 provides an overview of Plaque Psoriasis (Psoriasis Vulgaris) clinical trials scenario. This report provides top line data relating to the clinical trials on Plaque Psoriasis (Psoriasis Vulgaris). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

 

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Reasons to buy

 

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials 28

Prominent Drugs 29

Latest Clinical Trials News on Plaque Psoriasis (Psoriasis Vulgaris) 30

May 15, 2018: Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya) 30

May 10, 2018: NeuClone Announces Preclinical Results for Stelara (ustekinumab) Biosimilar Candidate 30

Apr 30, 2018: Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis 30

Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology 31

Apr 09, 2018: Skilarence is accepted for restricted use within NHS Scotland 31

Mar 06, 2018: Can-Fite to Provide Update on its Lead Drug Candidate Piclidenoson in NASH at the 30th Annual ROTH Conference 32

Clinical Trial Profile Snapshots 33

Appendix 641

Abbreviations 641

Definitions 641

Research Methodology 642

Secondary Research 642

About GlobalData 643

Contact Us 643

Source 643


List Of Figure

List of Figures

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 14

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2018* 15

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2018* 18

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

GlobalData Methodology 642


List Of Table

List of Tables

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region, 2018* 7

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries, 2018* 12

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 14

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2018* 15

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2018* 18

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase, 2018* 21

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Plaque Psoriasis (Psoriasis Vulgaris) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CROs, Terminated, Suspended and Withdrawn trials of Plaque Psoriasis (Psoriasis Vulgaris), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

LEO FoundationNovartis AGJohnson & JohnsonAbbVie IncPfizer IncEli Lilly and CoAmgen IncCelgene CorpAstellas Pharma IncGlaxoSmithKline Plc

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018

 

Summary

 

GlobalData's clinical trial report, Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H1, 2018 provides an overview of Plaque Psoriasis (Psoriasis Vulgaris) clinical trials scenario. This report provides top line data relating to the clinical trials on Plaque Psoriasis (Psoriasis Vulgaris). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

 

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Reasons to buy

 

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Five Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Subjects Recruited Over a Period of Time 25

Clinical Trials by Sponsor Type 26

Prominent Sponsors 27

Top Companies Participating in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials 28

Prominent Drugs 29

Latest Clinical Trials News on Plaque Psoriasis (Psoriasis Vulgaris) 30

May 15, 2018: Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya) 30

May 10, 2018: NeuClone Announces Preclinical Results for Stelara (ustekinumab) Biosimilar Candidate 30

Apr 30, 2018: Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis 30

Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology 31

Apr 09, 2018: Skilarence is accepted for restricted use within NHS Scotland 31

Mar 06, 2018: Can-Fite to Provide Update on its Lead Drug Candidate Piclidenoson in NASH at the 30th Annual ROTH Conference 32

Clinical Trial Profile Snapshots 33

Appendix 641

Abbreviations 641

Definitions 641

Research Methodology 642

Secondary Research 642

About GlobalData 643

Contact Us 643

Source 643


List Of Figure

List of Figures

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 14

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2018* 15

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2018* 18

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 21

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 22

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 26

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

GlobalData Methodology 642


List Of Table

List of Tables

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Region, 2018* 7

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, North America, Top Countries, 2018* 12

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 14

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, G7 Countries (%), 2018* 15

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17

Proportion of Plaque Psoriasis (Psoriasis Vulgaris) to Immunology Clinical Trials, E7 Countries (%), 2018* 18

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 20

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Phase, 2018* 21

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 22

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 23

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 24

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 25

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 26

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 27

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 28

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Plaque Psoriasis (Psoriasis Vulgaris) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CROs, Terminated, Suspended and Withdrawn trials of Plaque Psoriasis (Psoriasis Vulgaris), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

LEO FoundationNovartis AGJohnson & JohnsonAbbVie IncPfizer IncEli Lilly and CoAmgen IncCelgene CorpAstellas Pharma IncGlaxoSmithKline Plc